---

$2.07

+0.0050 ( +0.24% ) 4.4M

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, primarily generated from collaborations and licensing agreements, supports their research and development efforts.

Type: All Buy Sale Start date: End date: Filter Reset

Date	Type	Amount Purchased	Purchaser
2024-06-20	Sale	-18641.00	MESSEMER DEBORAH M.
2024-06-07	Sale	-61475.00	SATO VICKI L
2024-06-07	Sale	-191082.00	Barrett Elizabeth A.
2024-06-07	Sale	-191082.00	Mayo Stephen